Posted on 25th November 2014
Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.
It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.
22nd April 2021
After a year like no other, we are especially impressed by our optometrist, Rebecca Daly, who is one of the first individuals to have gained the NHS Education for Scotland Glaucoma Award Training (NES...Read more
14th April 2021
Myopia is expected to affect 50% of the world population by 2050. In the UK, the amount of myopia has increased from 10% to 23% of children in the past 50 years. In the past year, we have noticed an i...Read more